Michael Leung, PharmD, BCOP

home / authors / michael-leung-pharmd-bcop

Articles

A panel of 4 experts on colorectal cancer

Unmet Needs and Future Perspectives in Colorectal Cancer

John Strickler, MD;Arvind N. Dasari, MD, MS;Michael Leung, PharmD, BCOP;Margot O’Neill, PA-C, MHS
May 9th 2024

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

Read More

A panel of 4 experts on colorectal cancer

Multidisciplinary Care for Patients with CRC

John Strickler, MD;Arvind N. Dasari, MD, MS;Michael Leung, PharmD, BCOP;Margot O’Neill, PA-C, MHS
May 2nd 2024

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Read More

A panel of 4 experts on colorectal cancer

Toxicity Considerations and Treatment Decisions in CRC

John Strickler, MD;Arvind N. Dasari, MD, MS;Michael Leung, PharmD, BCOP;Margot O’Neill, PA-C, MHS
May 2nd 2024

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Read More

Michael Leung, PharmD, an expert on colorectal cancer

Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

John Strickler, MD;Arvind N. Dasari, MD, MS;Michael Leung, PharmD, BCOP;Margot O’Neill, PA-C, MHS
April 18th 2024

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Read More

A panel of 4 experts on colorectal cancer

Treatment Considerations With Regorafenib in Colorectal Cancer

John Strickler, MD;Arvind N. Dasari, MD, MS;Michael Leung, PharmD, BCOP;Margot O’Neill, PA-C, MHS
April 18th 2024

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Read More

John H. Strickler, MD, associate professor, medicine, member, the Duke Cancer Institute; Michael Leung, PharmD, BCOP, clinical pharmacy specialist, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center; Arvind N. Dasari, MD, MS, associate professor, the Department of GI Medical Oncology, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Margot O’Neill, PA-C, MHS, physician assistant, oncology, the Duke Cancer Institute

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

John Strickler, MD;Arvind N. Dasari, MD, MS;Michael Leung, PharmD, BCOP;Margot O’Neill, PA-C, MHS
March 25th 2024

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Read More

Latest Updated Articles

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer